Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding 15% over the next 6-12 months [3]. Core Insights - The company is projected to achieve nearly 10% revenue growth in 2024, with a net loss not exceeding 275 million USD, representing a reduction of over 58% compared to the previous year [1][2]. - The overseas business is expected to see an approximately 80% year-on-year revenue increase, benefiting from the synergies and efficiencies of a global platform [1]. - The company has focused on core business areas, leading to stable revenue growth and a significant reduction in losses through various measures, including cost-cutting and business focus [2]. Summary by Sections Revenue and Profitability - The company anticipates a revenue of 1,045 million USD in 2024, with a growth rate of 10% [5]. - The net loss is projected to decrease to 270 million USD in 2024 and further to 59 million USD in 2025, with a forecasted profit of 91 million USD in 2026 [5][9]. Business Segments Performance - The company's key segments include: - Artery and peripheral vascular intervention business, with a revenue growth of approximately 1.6% [2]. - Neuro-intervention business achieving double-digit growth [2]. - Heart valve business overseas revenue growth exceeding 100% [2]. - Surgical robotics business revenue growth estimated at 145%-155% [2]. Research and Development - The company is a leading player in high-value consumables, with R&D investments of 115 million USD in the first half of 2024 [3]. - As of the end of 2024, the company has 36 green channel products and has received multiple regulatory approvals, including 46 Class III medical device registrations in China and 184 overseas [3]. Financial Forecasts - The financial forecasts indicate a steady increase in revenue and a gradual reduction in losses, with expected revenues of 1,198 million USD in 2025 and 1,373 million USD in 2026 [5][9]. - The earnings per share (EPS) is projected to improve from -14.63 cents in 2024 to 4.92 cents in 2026 [5][9].

ADC CRDMO 龙头，一体化平台赋能 药明合联(2268) ——药明合联首次覆盖报告 | [Table_Industry] | | --- | | 医药 | | [Table_Invest] | | --- | | 评级： 增持 | | [table_Authors] 丁丹(分析师) | 吴晗(分析师) | | | | --- | --- | --- | --- | | | | [当前价格 Table_CurPrice] (港元)： | 35.20 | | 0755-23976735 | 010-83939773 | | | | dingdan@gtjas.com | wuhan024878@gtjas.com | [Table_Market] | | | 登记编号 S0880514030001 | S0880523080005 | 交易数据 | | 本报告导读： 全球 ADC CRDMO 市场持续扩容，公司漏斗管线推进业绩增长，"双厂战略"保障 产能建设，研发能力增强客户粘性。抢滩布局 XDC，打造第二增长曲线。首次覆盖， 给予增持评级。 投资要点： [首次覆盖，给予增持评级。 Table_Summar ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [4]. Core Insights - The company's 2024 full-year performance fell short of expectations, with revenue of $4.451 billion, a year-on-year increase of 6%, but below the Bloomberg consensus estimate of $4.566 billion. Net profit reached $154 million, up 19% year-on-year, but also below the expected $187 million [1][4]. - The company anticipates a revenue growth of 5-15% for 2025, significantly lower than the Bloomberg consensus estimate of 25% [1][4]. - The demand for AI servers remains robust, contributing to the growth in the network infrastructure segment, which is expected to maintain double-digit growth in Q1 2025 [2]. Summary by Sections Financial Performance - In 2024, the company achieved a net profit of $154 million, with a net profit margin of 3.5%, reflecting a 0.4 percentage point increase year-on-year. The growth in profitability is attributed to market demand recovery and a diversified product portfolio [1]. - Revenue breakdown for FY24 shows a decline in smartphone revenue by 9.7% to $943 million, while network infrastructure revenue grew by 39.1% to $591 million, and electric vehicle revenue surged by 57.6% to $481 million [1][2]. Business Segments - The network infrastructure segment is experiencing rapid growth due to increased demand for AI servers and related components. The company expects this segment to continue growing at over 15% in Q1 2025 [2]. - The automotive business is benefiting from acquisitions, with significant revenue growth expected following the integration of Voltaira and Kabel, both contributing to the electric vehicle market [2]. - The acoustic business saw slight revenue growth due to new product launches, which helped mitigate the impact of a weak consumer electronics market [3]. Profitability Forecast - The report projects a decline in smartphone ASP due to competitive pressures, leading to a downward revision of net profit forecasts for 2025 and 2026 to $242 million and $326 million, respectively [4][5]. - The company is expected to benefit from the growing demand for AI data centers, maintaining a positive outlook despite the challenges in the smartphone segment [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 3.18 per share [5]. Core Insights - The company is leveraging AI technology to enhance its core business operations, aiming for high-quality and efficient growth [1][2]. - The deployment of the proprietary "Li Hong AI System" is expected to improve operational efficiency and meet customized client needs in the energy testing sector [2]. - The company has shown strong performance in overseas markets, with significant revenue growth, particularly in the overseas segment, which increased by 47.2% year-on-year [3]. Financial Summary - The company reported a revenue of HKD 944.01 million for FY2022, with projections of HKD 1,368.11 million for FY2024, reflecting a growth rate of 22.3% [4][10]. - The net profit for FY2022 was HKD 69.40 million, expected to rise to HKD 89.05 million in FY2024, indicating a growth rate of 11.2% [4][10]. - The gross margin is projected to be around 41.8% in FY2024, with a net profit margin of 6.5% [4][10]. - The company’s return on equity (ROE) is expected to average 21.5% in FY2024, increasing to 25.7% by FY2026 [4][10]. Business Performance - The company’s revenue from the Greater China region reached HKD 340 million in H1 2024, showing a stable growth of 5.8% year-on-year, while overseas revenue was HKD 270 million, marking a substantial increase of 47.2% [3]. - The overseas business now accounts for 47% of total revenue, indicating a successful expansion strategy [3]. - The company is focusing on enhancing its brand recognition in overseas markets, particularly in Singapore, where it has seen rapid growth [3].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 3.18 per share [5]. Core Insights - The company is leveraging AI technology to enhance its core business operations, aiming for high-quality and efficient growth [1][2]. - The deployment of the proprietary "Li Hong AI System" is expected to improve operational efficiency and customer service customization [2]. - The company's overseas business has shown significant growth, with a 47.2% year-on-year increase in revenue from international markets [3]. Summary by Sections AI Application and Business Enhancement - The company has announced the application of AI in its inspection, operation, and testing processes, which is expected to enhance efficiency and meet diverse customer needs [1][2]. - Key technological advancements include the introduction of a "business language decoder" and a multi-modal knowledge graph [2]. Overseas Business Performance - In the first half of 2024, revenue from the Greater China region reached HKD 340 million, a steady growth of 5.8%, while overseas revenue surged to HKD 270 million, marking a substantial increase of 47.2% [3]. - The overseas business now accounts for 47% of total revenue, indicating a successful expansion strategy [3]. Financial Projections - The company forecasts revenue growth rates of 22.3% for FY2024 and 21.9% for FY2025, with net profit expected to grow by 11.2% in FY2024 and 35.0% in FY2025 [4][10]. - The projected earnings per share (EPS) are expected to increase from HKD 0.164 in FY2024 to HKD 0.222 in FY2025 [4][10].

Investment Rating - The investment rating for Geely Automobile is "Buy" and is maintained [6]. Core Views - Geely Automobile reported February 2025 sales of 205,000 vehicles, representing a year-on-year increase of 83.9% but a month-on-month decrease of 23.2% [2][4]. - Cumulative sales for January and February 2025 reached 472,000 vehicles, up 45.2% year-on-year [2][4]. - The company is expected to enter a new product era supported by the GEA platform, with strong performance across its brands including Zeekr, Lynk & Co, and Galaxy [2][4]. - The transition to new energy vehicles is progressing smoothly, with scale effects expected to enhance profitability [2][4]. - Geely's solid foundation in fuel vehicles and innovative overseas expansion strategies are opening new markets [2][4]. - The company is set to accelerate its AI smart driving capabilities, aiming to become a leader in smart automotive technology [2][4]. - The GEA platform is anticipated to drive a new cycle of technology and product development, with significant cost reductions and improved efficiency [2][4]. - Geely's sales target for 2025 is set at 2.71 million vehicles, with a projected year-on-year growth of 25% [2][4]. Summary by Sections Sales Performance - February 2025 sales were 205,000 vehicles, with a year-on-year increase of 83.9% and a month-on-month decrease of 23.2% [2][4]. - January-February 2025 cumulative sales reached 472,000 vehicles, up 45.2% year-on-year [2][4]. - Breakdown by brand: Geely brand sold 174,000 vehicles (+91.5% YoY), Zeekr sold 14,000 vehicles (+86.9% YoY), and Lynk & Co sold 17,000 vehicles (+30.5% YoY) [2][4]. New Energy Transition - New energy vehicle sales in February reached 98,000 units, a year-on-year increase of 193.8% [2][4]. - New energy vehicles accounted for 48.0% of total sales, up 18.0 percentage points year-on-year [2][4]. - The company aims for new energy vehicle sales to reach 1.5 million units in 2025, with a projected growth of 69% [2][4]. Strategic Initiatives - Geely is launching a comprehensive AI smart driving strategy, enhancing its technological capabilities [2][4]. - The GEA platform supports various energy forms and is expected to lead to a new cycle of product launches and profitability [2][4]. - The company is expanding its global presence, with over 16 models launched in more than 40 countries [2][4].

证券研究报告 | 公司深度 | 城商行Ⅱ 经济大省的成长性城商行 ——青岛银行首次覆盖 投资要点 青岛银行是深耕山东的成长性城商行，化债推动风险评价改善，网点加密和低 不良生成有望支撑较强的盈利增长，有利于青岛银行估值抬升。 公司画像：经济大省成长性城商行 （1）发展：青岛银行由原青岛地区 21 家城市信用社合并组建而成。发展至今， 青岛银行资产规模达到城商行中位水平，具有金租和理财牌照，综合能力强。 （2）区位：青岛银行深耕青岛，覆盖全省。山东经济体量大，青岛经济领航山 东，是青岛银行发展的良好基础。截至 24H1 末，青岛银行有 51%贷款投向青 岛，其余分布在山东其他城市。 （3）管理：①青岛银行股权结构均衡，具有地方国资+优质民企+外资银行的多 元化股权结构。24H1 财报披露，青岛银行前三大股东分别是海尔集团、意大利 联合圣保罗银行、青岛国信，分别持有青岛银行 18.14%、17.50%、14.99%的股 份（合并子公司口径）。②管理团队金融经验丰富，以董事长景在伦先生、行长 吴显明先生为代表的核心管理团队，银行管理经验丰富，专业能力突出。 财务分析：ROE 呈逐步改善态势 青岛银行 2022 年以 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 9.12, indicating an expected upside of over 20% from the current price of HKD 7.52 [6]. Core Insights - The company reported a total revenue of HKD 504 million for 2024, representing a year-on-year increase of 2544%, primarily due to a USD 70 million upfront payment from Merck. The net profit for 2024 was HKD 28.3 million, up 107% year-on-year [1]. - The clinical trial results for ABSK021 in the treatment of TGCT in the Phase III MANEUVER study were positive, achieving a 54.0% overall response rate (ORR) compared to 3.2% in the placebo group, with significant improvements in key secondary endpoints [2]. - The company is advancing its clinical trials for ABSK011, which has received approval for a Phase III registration trial, targeting advanced or unresectable HCC patients [4]. - The market for ACH (Achondroplasia) presents unmet medical needs, with a global incidence of 1 in 17,000 to 28,000 live births, indicating a significant patient population for potential treatments [5]. Summary by Sections Financial Performance - The company expects revenues of HKD 630 million in 2025, with an upward revision of 2026 revenues from HKD 617 million to HKD 684 million. The projected net profits for 2025 and 2026 are HKD 45 million and HKD 68 million, respectively, with an expected net profit of HKD 98 million in 2027 [6]. Clinical Development - ABSK021 has shown excellent efficacy and safety in its Phase III trials for TGCT, with a low rate of treatment-related adverse events and no evidence of cholestatic liver toxicity [2]. - The Phase II trial results for ABSK021 in cGvHD showed an overall response rate of 57.7%, with significant responses observed across various affected organs [3]. Market Potential - The report highlights the potential of FGFR2/3 inhibitors like ABSK061 in treating ACH, with a significant market opportunity given the prevalence of the condition and the limited current treatment options [5].

Investment Rating - The report maintains a "Buy" rating for JD Group, with a target price of 220.5 HKD per share, based on a valuation of 12x PE for the retail business in 2025 [3][4][9]. Core Insights - JD Group's Q4 2024 performance exceeded expectations, with revenue of 3469.9 billion CNY, representing a year-over-year increase of 13.4%, and a Non-GAAP net profit of 112.9 billion CNY, up 34.2% year-over-year [6][9]. - The company benefits from the "old-for-new" policy, which has significantly boosted revenue, particularly in the electronics sector, where revenue reached 1741.5 billion CNY, a 15.8% increase year-over-year [6][9]. - The report highlights a strong user engagement, with active user numbers and purchase frequency both showing double-digit growth for multiple consecutive quarters [6][9]. Financial Projections - Revenue forecasts for 2024-2026 are adjusted to 11588 billion CNY, 12586 billion CNY, and 13322 billion CNY, respectively, reflecting the positive impact of the "old-for-new" policy [3][9]. - Adjusted net profit estimates for the same period are projected at 436 billion CNY, 483 billion CNY, and 510 billion CNY, benefiting from an increased proportion of high-margin products [3][9]. - The report indicates that JD's retail segment is expected to maintain high single-digit to double-digit growth due to ongoing government subsidies and a favorable market environment [6][9]. Segment Performance - JD Retail achieved revenue of 3070.6 billion CNY in Q4 2024, a 14.7% year-over-year increase, with operating profit rising to 100.4 billion CNY [6][9]. - JD Logistics reported revenue of 521.0 billion CNY, up 10.4% year-over-year, with operating profit increasing by 37.1% [6][9]. - New business initiatives, including the launch of JD's food delivery service, are in early stages but are expected to leverage existing operational capabilities without significant immediate financial impact [6][9]. Shareholder Returns - In 2024, JD Group repurchased 2.553 million shares for approximately 36 billion USD, representing 8.1% of the total shares outstanding as of the end of 2023 [6][9]. - The company plans to distribute a dividend of 0.5 USD per share in 2024, totaling around 1.5 billion USD, with a new share repurchase program set to commence in September 2024 [6][9].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has received approval for the first Trop2 ADC lung cancer indication globally, which aligns with previous expectations [7] - The expansion of indications is favorable for commercialization in China, with the company expected to participate in the 2025 national medical insurance negotiations [7] - The potential of the product is gradually being realized, with ongoing global phase III studies for additional lung cancer indications [7] - 2025 is projected to be a pivotal year for the company's product commercialization, with several products expected to be approved [7] Financial Summary - Revenue projections for the company are as follows: - 2023A: 1,540.5 million RMB - 2024E: 1,746.8 million RMB (growth rate: 13.4%) - 2025E: 1,836.7 million RMB (growth rate: 5.2%) - 2026E: 2,877.2 million RMB (growth rate: 56.7%) [2] - The net profit attributable to the parent company is projected to be negative, with figures as follows: - 2023A: -574.1 million RMB - 2024E: -350.1 million RMB - 2025E: -434.6 million RMB - 2026E: -286.1 million RMB [2] - Earnings per share (EPS) is expected to improve from -2.53 in 2023A to -1.26 in 2026E [2] - The company anticipates significant revenue from the product Lukanosatuzumab, with projected sales of 47 million RMB in 2024, 960 million RMB in 2025, and 1,886 million RMB in 2026 [9]